Terrie Curran - Jan 19, 2023 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Signature
/s/ Larry Miller, Attorney-in-Fact for Terrie Curran
Stock symbol
PHAT
Transactions as of
Jan 19, 2023
Transactions value $
-$47,729
Form type
4
Date filed
1/20/2023, 06:39 PM
Previous filing
Nov 23, 2022
Next filing
Mar 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PHAT Common Stock Award $0 +97.5K +114.53% $0.00 183K Jan 19, 2023 Direct F1, F2
transaction PHAT Common Stock Sale -$47.7K -5.82K -3.19% $8.20 177K Jan 20, 2023 Direct F3
holding PHAT Common Stock 2.24K Jan 19, 2023 by 401(k)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PHAT Stock Option (Right to Buy) Award $0 +163K $0.00 163K Jan 19, 2023 Common Stock 163K $8.35 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs") granted on January 19, 2023. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of January 19, 2023, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
F2 Includes 1,408 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2023.
F3 Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.16 to $8.20. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The stock option will vest with respect to 25% of the shares of common stock on January 19, 2024, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.